Bone Marrow-Infiltrating Human Neuroblastoma Cells Express High Levels of Calprotectin and HLA-G Proteins

Fabio Morandi1,*, Paola Scaruffi2,*, Fabio Gallo3, Sara Stigliani2, Stefano Moretti4, Stefano Bonassi5, Claudio Gambini6, Katia Mazzocco2, Paolo Fardin7, Riccardo Haupt8, Giampaolo Arcamone9 on behalf of the Italian Cooperative Group for Neuroblastoma, Vito Pistoia1, Gian Paolo Tonini2,*; Maria Valeria Corrias1

1 Laboratory of Oncology, Gaslini Institute, Genoa, Italy, 2 Translational Oncopathology, National Cancer Research Institute, Genoa, Italy, 3 Molecular Epidemiology, National Cancer Research Institute, Genoa, Italy, 4 LAMSADE-CNRS, Université Paris Dauphine, Paris, France, 5 Clinical and Molecular Epidemiology, IRCCS San Raffaele Pisana, Rome, Italy, 6 Service of Pathology, Scientific Directorate, Gaslini Institute, Genoa, Italy, 7 Laboratory of Molecular Biology, Scientific Directorate, Gaslini Institute, Genoa, Italy, 8 Laboratory of Epidemiology and Biostatistics Section, Scientific Directorate, Gaslini Institute, Genoa, Italy, 9 Policlinico Università Bari, Bari, Italy

Abstract

Metastases in the bone marrow (BM) are grim prognostic factors in patients with neuroblastoma (NB). In spite of extensive analysis of primary tumor cells from high- and low-risk NB patients, a characterization of freshly isolated BM-infiltrating metastatic NB cells is still lacking. Our aim was to identify proteins specifically expressed by metastatic NB cells, that may be relevant for prognostic and therapeutic purposes. Sixty-six Italian children over 18 months of age, diagnosed with stage 4 NB, were included in the study. Metastatic NB cells were freshly isolated from patients’ BM by positive immunomagnetic bead manipulation using anti-GD2 monoclonal antibody. Gene expression profiles were compared with those obtained from archived NB primary tumors from patients with 5-y-follow-up. After validation by RT-qPCR, expression/secretion of the proteins encoded by the up-regulated genes in the BM-infiltrating NB cells was evaluated by flow cytometry and ELISA. Compared to primary tumor cells, BM-infiltrating NB cells down-modulated the expression of CX3CL1, AGT, ATP1A2 mRNAs, whereas they up-regulated several genes commonly expressed by various lineages of BM resident cells. BM-infiltrating NB cells expressed indeed the proteins encoded by the top-ranked genes, S100A8 and A9 (calprotectin), CD177 and CD3, and secreted the CXCL7 chemokine. BM-infiltrating NB cells also expressed CD271 and HLA-G. We have identified proteins specifically expressed by BM-infiltrating NB cells. Among them, calprotectin, a potent inflammatory protein, and HLA-G, endowed with tolerogenic properties facilitating tumor escape from host immune response, may represent novel biomarkers and/or targets for therapeutic intervention in high-risk NB patients.

Introduction

Metastasis is the main cause of death in patients with neuroblastoma (NB) [1–3]. In spite of aggressive multimodal therapy, children under 18 months of age, presenting at diagnosis with dissemination of malignant neuroblasts in the bone marrow (BM), have a grim prognosis [1,2]. To achieve efficient targeted-based therapies for high risk NB patients, characterization of the genetic and biological features of metastatic cell is therefore required.

In recent years, extensive characterization of primary tumor cells from high-risk NB patients has been performed. DNA abnormalities [4], gene expression profiles [5–7], and non-coding RNAs expression [8,9] have been proposed as sensitive indicators of NB tumor aggressiveness. Recently, a great effort has been performed in order to validate the gene classifiers on independent patient cohorts [7,10]. However, no information is presently available on freshly isolated BM-infiltrating NB cells, with the exception of few features [11,12]. After in vitro culture of BM samples from patients with metastatic disease, Hansford et al. [13] isolated cells endowed with high tumorigenic potential, suggesting that metastatic cells may be enriched in tumor initiating cells (TICs). Recently, a gene expression profiling of TICs has been reported [14]. Culture conditions, however, may greatly change the neoplastic cell features. Based on the above considerations, we investigated the transcriptome of NB metastatic cells in comparison...
with that of primary tumor cells from patients with stage 4 disease. The proteins selectively overexpressed by the BM-infiltrating NB cells may represent novel prognostic markers and potential targets for biologically driven therapy for high risk NB patients.

Results

Characterization of BM-infiltrating GD2 positive cells

To ascertain whether genes expressed by the GD2 positive fractions can be fully ascribed to the BM-infiltrating NB cells, six freshly isolated GD2 positive cell populations were characterized using different methodologies. As shown in Figure 1A-B, FISH analysis performed on GD2 positive cell preparations from two patients with MYCN amplification showed presence of MYCN amplification. Cytospins of GD2 positive cell preparations were enriched in mononuclear NB cells expressing the NB-specific markers GD2, CD56 [15] and NB84 [16] (Figure 1C, D and E, respectively). Cytotuorimetric analysis showed that less than 5% of the cells recovered by GD2-positive immunomagnetic bead manipulation expressed CD45, whereas more than 95% expressed the B7H3 antigen (Figure 1F and G, respectively). Previous studies showed that B7H3 is not expressed by hematopoietic and stromal BM cells [12,17]. Finally, all GD2 positive cell preparations expressed the NB-specific molecular markers TH, GD2 synthase, Phox2b, DCX, STX and ELAV4 [18], at the same levels as primary tumors, as assessed by RT-qPCR (Figure 2H). Taken together, these results indicated that the GD2 positive fractions were enriched in metastatic NB cells.

Gene expression profiling of BM-infiltrating NB cells

To identify genes specifically over- and under-expressed by BM-infiltrating NB cells compared with primary tumor cells, eleven freshly isolated GD2 positive preparations and twenty-one archived NB primary tumors were analyzed by microarrays. Eleven tumors were from alive patients and ten from patients who died of the disease at 5-year follow-up (Figure 2). The genes differently expressed in the three groups were identified by applying the significance analysis of microarrays (SAM) by paired comparisons with a false discovery rate (FDR) = 1%. As shown in Figure 3A–C, the samples from the three groups were placed on different trunks of unsupervised hierarchical clustering dendrograms, which demonstrated that the selected sequences successfully classified the biological specimens.

The expression profile of the BM-infiltrating cells differed from that of primary tumor cells from stage 4 patients dead at 5-year follow-up in 970 probe sets (corresponding to 332 up-regulated and 638 down-regulated unique transcripts), whereas 3158 probe sets (corresponding to 1366 up-regulated and 1253 down-regulated unique transcripts) were differently expressed compared to primary tumor cells from stage 4 patients alive at 5-year follow-up (Table S1). When compared to all twenty-one primary tumors the BM-infiltrating GD2 positive cells differed in 3146 probe sets, corresponding to 1435 down-regulated and 1224 up-regulated unique transcripts (Table S1).

The genes down-modulated in BM-infiltrating cells compared to primary tumor cells, irrespective of patient outcome, not surprisingly were genes necessary to sustain an organized, tri-dimensional structure, as that of a primary tumor, involving cell matrix signaling and adhesion, cell differentiation and blood vessel development pathways (Table S2). The down-modulation of top-ranked genes (namely, AGT, ATP1A2, BLK, CX3CL1, IGSF1, IGFBP3, and TNC) was then tested by RT-qPCR in a subset of samples hybridized to microarrays (5 samples from each group, Figures S1, S2 and S3). CX3CL1, AGT, ATP1A2, and IGSF1 mRNAs proved to be significantly down-modulated in the BM-infiltrating GD2 positive fractions compared to primary tumor cells (P<0.0001, P = 0.0325, P = 0.0196, P = 0.0047, respectively). These results were further confirmed in an independent set of 15 additional samples (5 for each group, Figures S4, S5 and S6) (P = 0.0013, P = 0.0012, P = 0.0023, P = 0.0014, respectively). It is noteworthy that CX3CL1 (also called fractalkine) was down-modulated irrespective of patient outcome, whereas AGT and ATP1A2 were down-modulated only compared to primary tumor cells from patients alive at 5-year follow-up (Figures S2, S3, S5, S6), which suggests that they may represent novel surrogate markers of tumor aggressiveness.

Among the genes significantly up-regulated in the BM-infiltrating GD2 positive cells compared to primary tumor cells (Table 1 and Table S2) several genes were commonly expressed by various lineages of BM resident cells, namely: i) cathelicidin (LL-37, myeloperoxidase (MPO), myeloid cell differentiation antigen (MNDA), CD177, FC receptor, CD69 expressed by myelomonocytic cells; ii) mu chain, CD19, and BLK expressed by B cells and iii) IL-1β, IL-6, and CXCL7 (PPBP) expressed by several hematopoietic and mesenchymal cells. To exclude that these findings were due to the small amount of normal resident BM cells present in our GD2 positive cell fractions, we directly checked whether the BM-infiltrating NB cells expressed the proteins encoded by these genes.

Expression and/or release of proteins encoded by up-regulated genes in BM-infiltrating GD2 positive cells

The surface membrane expression of CD177, CD37, and calprotectin, encoded by the S100A8 and S100A9 genes, was assessed by cytotofluorimetric analysis in ten fresh BM samples from stage 4 patients with a median infiltration of 13% of GD2 positive cells (range 2.5–33%), as assessed by anti-GD2 immunocytochemistry [19]. We also tested 3 membrane proteins expressed by NB side population cells, namely: CD133, CD117 (c-kit) and CD271 (p75), and HLA-G, a monomorphic HLA class I molecule, whose expression was not previously found in NB primary tumors [20]. As shown in Table 2, the BM-infiltrating GD2 positive cells co-expressed CD177 and CD37 only in 3/9 and 3/6 BM samples, respectively. Moreover, only 30% of the GD2 positive cells co-expressed each of the two proteins (Table 2). Conversely, the BM-infiltrating GD2 positive cells co-expressed HLA-G and the S100A8/S100A9 complex (calprotectin) in 9/9 and 6/6 BM samples, respectively. Most importantly, 100% of the GD2 positive cells co-expressed both proteins (Table 2). With respect to NB side population markers, 100% of GD2 positive cells in 4/4 BM samples co-expressed p75, approximately 80% of GD2 positive cells co-expressed c-kit in 4/10 samples, while none of 7 GD2 positive cell preparations co-expressed CD133 (Table 2).

Then we performed FACS analysis on three freshly-isolated GD2 positive cell preparations to further confirm co-expression of HLA-G and calprotectin by the BM-infiltrating NB cells. As shown in Figure 4, the GD2 positive cells were CD45 negative, expressed the B7H4 and CD56 NB-specific markers, and co-expressed HLA-G and calprotectin, whereas c-kit, CD37 and CD177 were co-expressed by a fraction of cells.

Next, we investigated whether freshly isolated BM-infiltrating GD2 positive cells could release IL-1β, CXCL1, and CXCL7 in the culture supernatant. Conditioned media from three preparations cultured for 48 hours were tested by ELISA. As reported in Table 2, all three GD2 positive preparations released CXCL7 (mean = 1.39 µg/mL), 1 out of 3 released CXCL1 (0.91 µg/mL) and none released IL-1β.
Figure 1. Characteristics of freshly isolated GD2+ fractions from stage 4 NB patients. (A, B) FISH analysis of two GD2 positive cell preparations from two patients with MYCN amplified tumors; (C, D, E) Cytospins of a GD2 positive cell preparation tested with anti-GD2 mAb (different from the one used for immunomagnetic bead separation), anti-NB84 mAb, and anti-CD56 mAb, respectively; (F, G) cytofluorimetric analysis.
Discussion

The aim of this study was to identify genes and proteins differentially expressed by BM-infiltrating NB cells that could be new potential therapeutic target and/or prognostic factors for high risk NB patients. The results showed a significant down-regulation of genes involved in extracellular matrix-cell adhesion pathways and in blood vessel development. The genes more significantly down-modulated were CX3CL1, AGT, and ATP1A2. CX3CL1 (fractalkine) is a neuronal chemokine capable of inducing immune effector cell migration, adhesion and IFN-γ secretion [21]. Intriguingly, CX3CL1 down-modulation was observed in MYCN-amplified primary NB tumors [22], supporting a role in limiting tumor aggressiveness. AGT and ATP1A2 down-modulations were significantly associated with patient outcome, which suggests that expression of these proteins in primary tumors may have a prognostic value. AGT encodes angiotensinogen, the precursor of angiotensin, a key protein involved in blood vessel formation, and ATP1A2 is a sodium-potassium ATPase, implicated in ion-exchange signaling. Further studies in larger cohorts of NB patients, however, are needed to address their prognostic role.

In keeping with the specific aim of our study we focused instead on the up-regulated genes. The BM-infiltrating GD2 positive cells compared to primary tumor cells over-expressed several genes that are normally expressed by different lineages of resident BM cells. Our GD2 positive cell preparations were enriched in CD56+ and NB84+ mononuclear NB cells, showed the same genetic aberration as the primary tumor cells, and expressed NB-specific genes, such as TH, GD2 synthase, Phox2b, ELAV4 and DCX, at the same levels as primary tumor cells. However, they could not be considered pure, therefore to avoid bias we evaluated the expression of the proteins encoded by these genes in fresh BM samples from stage 4 patients, together with proteins specifically expressed by NB cells, by NB cell side population, and NB TICs. Whereas in unprocessed BM samples from healthy individuals GD2 expression is absent [23], in BM samples from stage 4 NB patients GD2 positive cells represented about 20–30% of mononuclear cells and 100% of these cells always co-express NB proteins.

Figure 2. Study design. Freshly isolated GD2 positive cells were obtained by positive immunomagnetic bead manipulation of BM aspirates, as described in M&M section. Primary NB tumors were stored in the Tissue Repository at the Gaslini Institute.

doi:10.1371/journal.pone.0029922.g001
specific markers, as p75, CD56, and B7H3, thus confirming that the GD2-positive BM-infiltrating cells were indeed metastatic NB cells. Surface expression of CD133 never occurred whereas expression of CD177 and CD37, two clusters of hematopoietic differentiation, was occasionally detected in fractions of BM-infiltrating GD2 positive cells, in a way similar to CD117 (c-kit). Expression of CD37, a member of the tetraspanin family, has been involved in metastasis [24], while nothing is known about the possible role in cancer of CD117, a glycosyl-phosphatidylinositol (GPI)-linked surface protein, normally secreted by neutrophils [25]. Thus, our findings suggest that the role, if any, of CD133, CD117, CD37 and CD177 can not be pivotal in determining the aggressiveness of the metastatic cells. Similarly, CXCL1 secretion was not consistent, even if CXCL1 was shown to accelerate tumor growth, angiogenesis, and stromal recruitment during the metastatic process in melanoma, breast and colon cancer [26].

Conversely, the BM-infiltrating GD2 positive cells released the chemokine CXCL7, encoded by the PPBP gene. CXCL7 was found over-expressed in breast cancer patients [27], and CXCL7-transfected breast cancer cells were more invasive than parental cells [28]. More interestingly, all freshly isolated GD2 positive cells co-expressed not only CD56 and B7H3 proteins [29,30], but also calprotectin and HLA-G. The heterodimeric protein calprotectin, a product of the S100A8 and S100A9 genes, is a member of the S100 protein family, composed of small (10–12 kDa) acidic calcium and zinc binding proteins. Calprotectin is normally expressed by phagocytes and polymorphonuclear leukocytes. The S100A8/A9 complex is located in the cytosol and, upon elevation of intracellular calcium levels, is translocated to the cytoskeleton and then to the plasma membrane. Lacking a trans-membrane signaling domain, calprotectin remains attached by non-covalent association and, during inflammation, the S100A8/A9 complex is released into biological fluids. Calprotectin may induce apoptosis of different cell types, through zinc sequestration, and it has been widely used as biomarker of inflammation [31]. Moreover, calprotectin has been identified as a potent ligand of the Toll-like receptor 4 (TLR4) [32], which is responsible for specific response to endogenous danger signals. Since we recently demonstrated [33] that resident BM cells from patients with NB up-regulated the expression of genes involved in inflammation and response to biotic stimuli, it is tempting to speculate that calprotectin may be one of the signals involved.

In spite of its properties as enhancer of innate immune responses, calprotectin was found selectively expressed by invasive breast [34] and thyroid [35] cancer cells. Recently, its expression was associated with cancer progression and metastasis in different

**Figure 3. Gene expression profiling.** Hierarchically clustered heat maps of differentially expressed probe sets in BM-infiltrating metastatic GD2 positive cells (GD2+) and (A) primary tumors from patients who died of stage 4 NB (NB_dead), (B) primary tumors from patients with stage 4 NB alive at 5 year follow-up (NB_RC), (C) primary tumors from patients with stage 4 NB, irrespective of outcome (NB). Each color patch represents the expression level of genes (row) in that sample (column), with a continuum of expression levels from bright green (lowest) to bright red (highest). Non-detected signals are indicated in white.

doi:10.1371/journal.pone.0029922.g003
Table 1. Top-ranked genes differentially expressed by BM-infiltrating metastatic GD2 positive cells (GD2+) and primary tumor cells from patients with stage 4 NB, dead and alive at 5-year follow-up, selected by SAM analyses.

| GeneName | Description | tumors stage 4 alive | GD2+ | Diff. Mean |
|----------|-------------|----------------------|------|------------|
| S100A9   | Homo sapiens S100 calcium binding protein A9 (calgranulin B) (S100A9), mRNA [NM_002965] | 5.66 | 12.89 | -7.23 |
| S100A8   | Homo sapiens S100 calcium binding protein A8 (calgranulin A) (S100A8), mRNA [NM_002964] | 8.55 | 15.09 | -6.55 |
| CAMP     | Homo sapiens cathelicidin antimicrobial peptide (CAMP), mRNA [NM_004345] | 5.3  | 11.52 | -6.21 |
| MPO      | Homo sapiens myeloperoxidase (MPO), nuclear gene encoding mitochondrial protein, mRNA [NM_000250] | 5.21 | 10.75 | -5.54 |
| MNDA     | Homo sapiens myeloid cell nuclear differentiation antigen (MNDA), mRNA [NM_002432] | 7.37 | 11.86 | -4.49 |
| CD177    | full-length cDNA clone CSD0I15Y017 of Placenta Cot 25-normalized of Homo sapiens (human). [CR592446] | 4.63 | 8.94 | -4.31 |
| LYZ      | Homo sapiens lysozyme (renal amyloidosis) (LYZ), mRNA [NM_000239] | 7.63 | 11.82 | -4.19 |
| FCAR     | Homo sapiens Fc fragment of IgA, receptor for (FCAR), transcript variant 1, mRNA [NM_002000] | 4.08 | 7.95 | -3.87 |
| LILRA2   | Homo sapiens leucocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2 (LILRA2), mRNA [NM_006866] | 4.4  | 8.1  | -3.7  |
| PPBP     | Homo sapiens pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) (PPBP), mRNA [NM_002704] | 5.28 | 8.88 | -3.59 |
| HSH2D    | Homo sapiens hematopoietic SH2 domain containing (HSH2D), mRNA [NM_032855] | 6.53 | 9.66 | -3.43 |
| IL1B     | Homo sapiens interleukin 1, beta (IL1B), mRNA [NM_000576] | 7.13 | 10.55 | -3.42 |
| NFE2     | Homo sapiens nuclear factor (erythroid-derived 2), 45kDa (NFE2), mRNA [NM_006163] | 7.08 | 10.45 | -3.37 |
| TREM1    | Homo sapiens triggering receptor expressed on myeloid cells 1 (TREM1), mRNA [NM_018643] | 4.39 | 7.71 | -3.32 |
| IL18RA1  | Homo sapiens interleukin 18 receptor accessory protein (IL18RAP), mRNA [NM_003853] | 6.68 | 9.92 | -3.24 |
| NCF1     | Homo sapiens neutrophil cytosolic factor 1, chronic granulomatous disease, autosomal 1 (NCF1), transcript variant 1, mRNA [NM_002065] | 7.54 | 10.78 | -3.24 |
| BLK      | Homo sapiens B lymphoid tyrosine kinase (BLK), mRNA [NM_001715] | 5.53 | 8.74 | -3.21 |
| P2RY2    | Homo sapiens purinergic receptor P2Y, G-protein coupled, 2 (P2RY2), transcript variant 1, mRNA [NM_0176072] | 5.43 | 8.58 | -3.15 |
| CD19     | Homo sapiens CD19 molecule (CD19), mRNA [NM_001770] | 7.62 | 10.64 | -3.02 |
| FCR5     | Homo sapiens Fc receptor-like 5 (FCR5), mRNA [NM_031281] | 5.58 | 8.59 | -3  |

| GeneName | Description | tumors stage 4 dead | GD2+ | Diff. Mean |
|----------|-------------|---------------------|------|------------|
| RNASE2   | Homo sapiens ribonuclease, RNase A family, 2 (liver, eosinophil-derived neutrotoxin) (RNASE2), mRNA [NM_002934] | 3.64 | 10.89 | -7.25 |
| S100A9   | Homo sapiens S100 calcium binding protein A9 (calgranulin B) (S100A9), mRNA [NM_002965] | 6.06 | 12.98 | -6.92 |
| S100A8   | Homo sapiens S100 calcium binding protein A8 (calgranulin A) (S100A8), mRNA [NM_002964] | 8.53 | 15.03 | -6.51 |
| S100P    | Homo sapiens S100 calcium binding protein P (S100P), mRNA [NM_005980] | 6.39 | 12.44 | -6.05 |
| MPO      | Homo sapiens myeloperoxidase (MPO), nuclear gene encoding mitochondrial protein, mRNA [NM_000250] | 4.77 | 10.68 | -5.91 |
| CAMP     | Homo sapiens cathelicidin antimicrobial peptide (CAMP), mRNA [NM_004345] | 5.75 | 11.38 | -5.63 |
| CD177    | Homo sapiens CD177 molecule (CD177), mRNA [NM_020406] | 3.87 | 9.17 | -5.3  |
| MNDA     | Homo sapiens myeloid cell nuclear differentiation antigen (MNDA), mRNA [NM_002432] | 7.1  | 12.16 | -5.06 |
| AQP9     | Homo sapiens aquaporin 9 (AQP9), mRNA [NM_020980] | 5.65 | 10.63 | -4.98 |
| RETN     | Homo sapiens resistin (RETN), mRNA [NM_020415] | 4.95 | 9.83 | -4.88 |
| LYZ      | Homo sapiens lysozyme (renal amyloidosis) (LYZ), mRNA [NM_000239] | 7.28 | 11.88 | -4.6  |
| LILRA3   | Homo sapiens leucocyte immunoglobulin-like receptor, subfamily A (without TM domain), member 3 (LILRA3), mRNA [NM_006865] | 5.03 | 9.48 | -4.45 |
| BLK      | Homo sapiens B lymphoid tyrosine kinase (BLK), mRNA [NM_001715] | 4.38 | 8.75 | -4.37 |
| FCAR     | Homo sapiens Fc fragment of IgA, receptor for (FCAR), transcript variant 1, mRNA [NM_002000] | 3.72 | 8.07 | -4.35 |
| CD19     | Homo sapiens CD19 molecule (CD19), mRNA [NM_001770] | 6.38 | 10.61 | -4.23 |
human tumors, which revealed that calprotectin is a Janus-faced molecule [36]. Hiratsuka et al. [37] demonstrated that the calprotectin-TLR4 axis guides metastatic cell invasion, and facilitates the survival and proliferation of cancer cells at the metastatic site. Thus, calprotectin expressed by BM-infiltrating metastatic NB cells may contribute to their survival and proliferation in the BM.

The BM-infiltrating GD2 positive cells also expressed HLA-G, a monomorphous HLA class Ib molecule, over-expressed in a wide variety of human cancers, endowed with tolerogenic properties facilitating tumor escape from host immune response [38]. Since primary NB tumors did not express HLA-G [20], it is conceivable that HLA-G may contribute to the high aggressiveness of BM-infiltrating NB cells throughout its immunosuppressive activity. Therefore, the search for drugs able to suppress HLA-G expression might increase the efficacy of immunotherapeutic intervention in high risk patients.

Further studies will be necessary to understand whether the expression of calprotectin and HLA-G by BM-infiltrating NB cells is transcriptionally regulated [39] or acquired by mechanisms such as cell fusion [40] or microvesicles [41]. Nonetheless, our study demonstrated that BM-infiltrating NB cells express genes not found in the primary tumor cells of patients with stage 4 disease, which may be responsible in part for their dismal prognosis. Since BM microenvironment in patients with localized and metastatic NB was similar despite their completely different outcomes [33], the identification of proteins specifically expressed by BM-infiltrating metastatic cells represents the only effective tool to find novel therapeutic targets and novel prognostic markers for high risk NB patients. In this view, calprotectin and HLA-G may deserve future studies.

### Materials and Methods

#### Study design

Sixty-six Italian children over 18 months of age, diagnosed with stage 4 NB according to INSS criteria [42] were included in the study. Diagnosis and staging were made at the referral center participating in the Italian Cooperative Group for Neuroblastoma. Central review of primary tumor histology was performed at the Gaslini Institute. Diagnostic work-up included evaluation of the primary tumor by appropriate imaging, morphological examination of two BM aspirates and at least one bone trephine biopsy, catecholamine metabolite assay in urine, ferritin and lactate dehydrogenase assays in serum, and evaluation of MYCN oncogene status in the primary tumor. Demographic, clinical and follow-up data were retrieved from the Italian Neuroblastoma Registry [43].

The study was approved by the Ethics Committees of each Italian Cooperative Group for Neuroblastoma center (http://www.aiecop.org/?q=mappa centri.html). All patients’ guardians signed a written consent allowing the use of samples and clinical data for research purposes. The procedures were in accordance with ethical standards and the Helsinki Declaration.

---

**Table 1. Cont.**

| GeneName | Description | tumors stage 4 dead | GD2+ | Diff. Mean |
|----------|-------------|---------------------|------|-----------|
| IL1B     | Homo sapiens interleukin 1, beta (IL1B), mRNA [NM_000576] | 6.48 | 10.68 | −4.2 |
| CD37     | Homo sapiens CD37 molecule (CD37), transcript variant 1, mRNA [NM_001774] | 6.46 | 10.37 | −3.91 |
| SIGLEC5  | Homo sapiens sialic acid binding Ig-like lectin 5 (SIGLEC5), mRNA [NM_003830] | 6.05 | 9.9 | −3.84 |
| VNN2     | Homo sapiens vanin 2 (VNN2), transcript variant 1, mRNA [NM_004665] | 7.06 | 10.83 | −3.77 |
| CXCL1    | Homo sapiens chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) (CXCL1), mRNA [NM_001511] | 6.78 | 10.52 | −3.74 |
| NCF1     | Homo sapiens neutrophil cytotoxic factor 1, chronic granulomatous disease, autosomal 1) (NCF1), mRNA [NM_000285] | 7.11 | 10.8 | −3.69 |
| FCR5     | Homo sapiens Fc receptor-like 5 (FCRL5), mRNA [NM_031281] | 4.87 | 8.55 | −3.68 |
| LILRA5   | Homo sapiens leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 5 (LILRA5), transcript variant 2, mRNA [NM_181985] | 4.64 | 8.32 | −3.68 |
| P2RY2    | Homo sapiens purinergic receptor P2Y, G-protein coupled, 2 (P2RY2), transcript variant 1, mRNA [NM_176072] | 5.17 | 8.81 | −3.64 |
| CD69     | Homo sapiens CD69 molecule (CD69), mRNA [NM_001781] | 7.29 | 10.9 | −3.62 |
| IL8RB    | Homo sapiens interleukin 8 receptor, beta (IL8RB), mRNA [NM_001557] | 4.11 | 7.51 | −3.4 |

doi:10.1371/journal.pone.0029922.t001

**Table 2. Surface expression and identification of released proteins encoded by genes up-regulated in BM-infiltrating GD2 positive preparations, as assessed by cytfluorimetric analysis a and ELISA b.**

| Protein | Number of samples | Positive (N) | % | Mean of co-expression |
|---------|-------------------|--------------|---|----------------------|
| CD177   | 9                 | 3            | 33 | 30.5                 |
| CD37    | 6                 | 3            | 50 | 29.0                 |
| HLA-G   | 9                 | 9            | 100| 100                  |
| Calprotectin | 6     | 6            | 100| 100                  |
| CD271   | 4                 | 4            | 100| 100                  |
| CD117   | 10                | 4            | 34 | 77.7                 |
| CD133   | 7                 | 0            | 0  | 0                    |
| CXCL1   | 3                 | 3            | 100| 100                  |
| IL-1β   | 3                 | 1            | 33 | 33                   |

apercentage of double positive cells.
bBassili et al., Cancer Chemother Pharmacol 2010; 65:1047–56.
Hirschmann-Jax et al., Proc Natl Acad Sci U S A 2004;101:14228–33.
Komuro et al., J Pediatr Surg 2007;42: 2040–45, Tong et al, World J Pediatr 2008;4:58–62.
doi:10.1371/journal.pone.0029922.t002
As depicted in Figure 1, archived primary NB tumors and freshly isolated GD2 positive BM-infiltrating NB cells collected at diagnosis were included in the study. All tumors were classified as Schwannian stroma poor NBs according to the International Neuroblastoma Pathology Committee [44]. They contained at least 80% of neuroblastoma cells, as assessed by the pathologist (CG). Three tumors showed MYCN amplification, one in the first group and two in the second group. The use of primary tumors stored in the Gaslini tumor repository “Biobanca integrata tessuogenomica” was approved by the Gaslini’s Ethics Committee.

Immunomagnetic separation of BM-infiltrating NB cells

To isolate BM-infiltrating NB cells, fresh BM samples from patients with stage 4 disease older than 18 months at diagnosis, containing 10–30% of NB cells, as assessed by immunocytochemical analyses [19] were subjected to immunomagnetic bead manipulation, as described in details in Scaruffi et al. [33]. The GD2 positive fraction, containing less than 5% of CD45+ hematopoietic cells as assessed by flow cytometry, was centrifuged and the cell pellet subjected to further analyses (Figure 1). The amount of recovered GD2 positive cells was around 10⁶/mL of BM sample.

Cytofluorimetric analysis

For characterization of GD2 positive cell preparations (Figure 1), surface membrane staining was done using the anti-B7H3 (5B14), kindly provided by Prof. A. Moretta [30] and the anti-CD45 (Becton Dickinson, San Jose, CA) monoclonal antibodies (mAbs). To evaluate surface protein expression by GD2 positive cells, whole BM samples from ten stage 4 NB patients and three freshly isolated BM-infiltrating GD2+ cells were stained with the following mAbs: anti-GD2 [purified from the G2a hybridoma cell line [45]], anti-B7H3 (5B14), anti-p75 (Novus Biologicals, Littleton, CO), anti-HLA-G PE (Exbio, Prague, CZ), anti-calprotectin FITC (BMA Biomedicals, Augst, Switzerland), anti-CD177 FITC (Becton Dickinson), anti-CD37 FITC (Becton Dickinson), anti-CD133 APC (Miltenyi Biotech, Bergisch Gladbach, Germany), anti-CD117 PE (Miltenyi Biotech), anti-CD45 FITC (Becton Dickinson) and anti-CD56 PC7 (Beckman Coulter, Brea, CA). Irrelevant isotype-matched mAbs, used at the same concentration as the test mAbs, were used as negative control. One × 10⁶ events were acquired using a Gallios Cytometer (Beckman Coulter) and data were analyzed with the Kaluza software (Beckman Coulter). The percentage of positive cells was calculated using a threshold line based on the maximum fluorescence intensity obtained with the irrelevant isotype-matched mAb.

Immunocytochemistry of GD2 positive cell preparations

Immunocytochemical labeling was performed according to standardized procedures for BM samples [46]. Briefly, cytospins of freshly isolated GD2 positive cells were fixed in 4% buffered paraformaldehyde for 10 minutes. After washing with PBS, cytospins were incubated for 30 minutes with proper dilutions of unlabeled anti-GD2 (Becton Dickinson), anti-NB84 and anti-CD56 (both from Dako, Glostrup, Denmark) in 1% PBS/BSA (Gibco, Paisley, UK). After washing in PBS, cytospins were incubated for 30 minutes with an unlabeled secondary antibody (Dako) diluted in 1% PBS/BSA. After washing, staining was obtained by incubation with APAAP complex (Dako) and Fuchsin+Substrate Chromogene System (Dako). Cytospins were counterstained with

Figure 4. Flow cytometric analysis of BM samples. A representative cytofluorimetric analysis of a freshly isolated GD2 positive cell preparation, tested with anti-B7H3 (5B14) and anti-GD2 mAb in combination with: anti-CD45, anti-HLA-G, anti-calprotectin, anti-CD56, anti-CD117 (c-kit), anti-CD37 and anti-CD177. The first plot shows anti-B7H3 specific mAb fluorescence intensity (Y axis) versus side-scatter (X axis), whereas all the other plots show specific mAb fluorescence intensity (Y axes) versus anti-GD2 specific mAb fluorescence intensity (X axes). Letters indicated in each panel are assigned from Kaluza software to each different single sample analysis. “++” indicates double positive cells (upper right panel), “+” and “-” indicate single positive cells (upper left and lower right panels), “-” indicates double negative cells (lower left panel). Percentages of single positive (first plot) or double positive (all the other plots) cells are indicated.

doi:10.1371/journal.pone.0029922.g004
hematoxylin (Sigma, St Louis, MO) and mounted in aqueous medium (Dako). As negative controls, slides were incubated with mouse normal serum (X0910, Dako) and processed as above.

**FISH analysis**

Double colour FISH was performed on interphase nuclei of GD2 positive cell preparations using the ON MYCN(2p24)/LAF(2q11) probe (Kreatech, Amsterdam, The Netherlands). Cytospins were pretreated with RNase and pepsin. Probes were handled according to the manufacturer’s protocol: slide and probe combinations were incubated simultaneously on a hot plate at 80°C for 5 min. Overnight incubation at 37°C, washes and DAPI nuclei counterstaining were done according to standard protocol. For each tumor at least 200 nuclei were surveyed. The terminology used was in accordance with the guidelines of the European Neuroblastoma Quality Assessment (ENQUA) group [47].

**Extraction of total RNA**

Total RNA was extracted from the GD2 positive cell preparations using the RNeasy Micro kit (Qiagen, Hilden, Germany), according to the manufacturer’s procedure that includes an RNase-free DNase I digestion to eliminate contaminating DNA. From primary NB tumors total RNA was extracted as previously described [9]. Quantification and quality control of total RNA were performed by RNA 6000 Nano® and Picog® assays on a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Only samples with RNA integrity number $\geqslant 6.0$ were included in the study.

**Gene expression profiling**

Five-hundred ng of total RNA were hybridized to Human GE 4x44K v2 Microarray Kit (Agilent Technologies) containing probes for 41,000 human transcripts following the One-color microarray-based gene expression analysis protocol (www.agilent.com), as described in detail in Scaruffi et al. [33]. All data is MIAME compliant and that the raw data has been deposited in National Center for Biotechnology Information Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO accession number GSE 25623a.

**Gene Ontology analysis**

DAVID software was used to determine biological pathways significantly over-represented in our datasets.

**Reverse transcription and quantitative real-time PCR (RT-qPCR)**

RNA (1 µg) was reverse transcribed using random primers and 120 U Superscript III (MMLV) reverse-transcriptase in a total volume of 20 µL (Invitrogen Life Technologies, Carlsbad, CA). cDNA was diluted 10-fold in molecular biology grade water to a final concentration of 5 ng/µL assuming 100% reverse transcription efficiency.

For GD2 positive cell characterization (Figure 1), level of expression of $\beta$-Tub, beta-1,4-N-acetyl-galactosaminyl transferase 1 (GD2-synthase), DCX, ELAV-4, Phox2b and STX was evaluated according to standardized conditions [48], using 8 primary NB tumors as positive controls.

For validation of microarray results (Figure 1), we first assessed ATP5B as the best reference gene for both GD2-positive and primary tumor cells by means of geNorm™ Housekeeping Gene Selection Kit and software (v. 3.4) (PrimerDesign Ltd, UK). Then, the expression of AGT, ATP1A2, BLK, CX3CL1, IGFBP3, IGF1 and TNC genes was quantified by pre-optimized FAM-labeled TaqMan® Gene Expression assays (Applied Biosystem, Foster City, CA). Negative controls (water as template and RNA reverse-transcribed without MMLV) and a positive control (cDNA from the IMR-32 NB cell line [40]) were always included. To determine the expression of each target gene relative to ATP5B, the equation $2^{\Delta\Delta Cq}$, where $\Delta Cq = (Cq_{target~gene} - Cq_{ATP5B})$, was calculated.

A checklist prepared according to the Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) is submitted as Supplementary Data.

**Secretion of cytokines**

Secretion of CXCL1, CXCL7, and IL-1β was assessed by using DuoSet ELISA Development System (R&D Systems, Minneapolis, MN), following manufacturer’s protocol. Brieﬂy, supernatants from three freshly separated GD2 positive cell preparations were collected after 48-hour culture in DMEM containing 20% FBS. H$_2$SO$_4$ 5 M (100 µL/well) was added to stop the reaction and optical densities were measured at 450 nm using Inﬁnite M200 reader (Tecan, Männedorf, Switzerland). The assay’s lowest threshold was 7.8 ng/mL for all analytes. Each sample was tested in duplicate.

**Statistical analysis**

Statistical analyses of gene expression proﬁling and of RT-qPCR data were performed as detailed in Scaruffi et al. (in press PBC). All signiﬁcance tests were two tailed and a P value $<0.05$ was considered as statistically significant.

**Supporting Information**

Table S1 Transcripts differentially expressed between BM-infiltrating GD2 positive cells and primary tumors from i) patients dead of stage 4 NB, ii) patients with stage 4 NB alive at 5 year follow-up, and iii) patients with stage 4 NB, irrespective of outcome, selected by SAM analysis. (PDF)

Table S2 The most significantly (P$<0.05$) enriched Gene Ontology Biological Process (GOBP) terms in gene signatures of BM-infiltrating GD2 positive cells and primary NB tumors from stage 4 patients. (XLS)

Figure S1 Box-and-Whisker plots of AGT, ATP1A2, BLK, CX3CL1, IGF1, IGFBP3, and TNC gene expression values by qPCR (normalized to ATP5B, and after logarithmic transformation of original measures) in 5 GD2 positive cells (GD2+) and 5 primary tumors (NB) previously hybridized to microarray. Each box represents the values from the 25th to 75th percentile, the middle line represents the median, and a line extends from the minimum to the maximum value, excluding outliers which are displayed as blue dots. (TIF)

Figure S2 Box-and-Whisker plots of AGT, ATP1A2, BLK, CX3CL1, IGF1, IGFBP3, and TNC gene expression values by qPCR (normalized to ATP5B, and after logarithmic transformation of original measures) in 5 GD2 positive cells (GD2+) and 5 primary tumors from patients dead of disease (NB_dead), previously hybridized to microarrays. Each box represents the values from the 25th to 75th percentile, the middle line represents the median, and a line extends from the minimum to the maximum value. (TIF)
Figure S3 Box-and-Whisker plots of AGT, ATP1A2, BLK, CX3CL1, IGSF1, IQGFP3, and TNC gene expression values by qPCR (normalized to ATP5B, and after logarithmic transformation of original measures) in 5 GD2 positive cells (GD2+) and 5 primary tumors from stage 4 patients (NB, alive), previously hybridized to microarrays. Each box represents the values from the 25th to 75th percentile, the middle line represents the median, and a line extends from the minimum to the maximum value, excluding outliers which are displayed as blue dots. (TIF)

Figure S4 Box-and-Whisker plots of AGT, ATP1A2, CX3CLI, and IGSF1 gene expression values by qPCR (normalized to ATP5B, and after logarithmic transformation of original measures) in 5 GD2 positive cells (GD2+) and 5 primary tumors from stage 4 patients (NB, alive), previously hybridized to microarrays. Each box represents the values from the 25th to 75th percentile, the middle line represents the median, and a line extends from the minimum to the maximum value, excluding outliers which are displayed as blue dots. (TIF)

Figure S5 Box-and-Whisker plots of AGT, ATP1A2, CX3CLI, and IGSF1 gene expression values by qPCR (normalized to ATP5B, and after logarithmic transformation of original measures) in 5 GD2 positive cells (GD2+) and 5 primary tumors from stage 4 patients (NB, alive) (independent sample set). Each box represents the values from the 25th to 75th percentile, the middle line represents the median, and a line extends from the minimum to the maximum value, excluding outliers which are displayed as blue dots. (TIF)

References
1. Spix C, Pastore G, Sankila R, Stillar CA, Stefanova-Foucher FE (2006) Neuroblastoma incidence and survival in European children (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer 42: 2001–2001.
2. Colhn SL, Pearson AD, London WB, Monclair T, Ambros PF, et al. (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27: 289–297.
3. Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, et al. (2009) Outcome of children with neuroblastoma after resection or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer 45: 2833–2842.
4. Bilke S, Chen QR, Wei JS, Khan J (2006) Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification. Clin Cancer Res 12: 5540–5547.
5. Aghazadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, et al. (2006) Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 98: 1193–1203.
6. Coco S, Defferrari R, Scaruffi F, Cavazzana A, Di Cristofano A, et al. (2005) Genome analysis and gene expression profiling of neuroblastoma and ganglion-neuroblastoma reveal differences between neuroblast and Schwannian stromal cells. J Pathol 207: 346–357.
7. Oberthuer A, Hero B, Berthold F, Jurcza D, Faldum A, et al. (2010) Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 28: 3506–3515.
8. Chen Y, Stallings RJ (2007) Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 67: 976–983.
9. Scaruffi P, Stigliani S, Moretti S, Coco S, De Vecchi C, et al. (2009) Transcript-Ultra Conserved Region expression is associated with outcome in high-risk neuroblastoma. BMC Cancer 9: 441.
10. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, et al. (2009) Human neuroblastomas isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 69: 11234–11243.
11. Morozova O, Voytische M, Grindeheim N, Hansdorff LM, Blakely KM, et al. (2010) System-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma. Cancer Res 70: 4572–4582.
12. Wachowiak L, Rawnqa T, Metzger R, Quaas A, Fieg H, et al. (2006) Universal expression of cell adhesion molecule NCAM in neuroblastoma in contrast to L1: implications for different roles in tumor biology of neuroblastoma? Pediatr Surg Int 22: 1361–1364.
13. Mertineit M, Chatten J, Partau A, Stevenson A (1998) Monoclonal antibody NR4 in the differential diagnosis of neuroblastoma and other small round cell tumors. Am J Surg Pathol 22: 327–332.
14. Gregorio A, Corrias MV, Castriconi R, Donzello A, Mosconi M, et al. (2008) Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of E743 surface molecule. Histopathology 53: 73–80.
15. Beinke K, Burchill SA, Cheung IV, Hyanna E, Seeger RC, et al. (2009) Consensus criteria for sensitive detection of minimal residual neuroblastoma in bone marrow, blood and stem cell preparations by immunocytochemistry and QRT-PCR recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 100: 1627–1637.
16. Corrias MV, Parodi S, Hauto R, Licitra G, Negri F, et al. (2008) Detection of GD2-positive cells in bone marrow samples and survival of patients with localized neuroblastoma. Br J Cancer 98: 263–269.
17. Morandi F, Levreri I, Bocca P, Galleni B, Raffaghello L, et al. (2007) Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res 67: 6433–6441.
18. Stevano L, Pievan E, Amadori A (2004) C and CX3C chemokines: cell sources and physiopathological implications. Crit Rev Immunol 24: 205–228.
19. Zeng Y, Haeberner N, Nest S, Weider S, Schroder U, et al. (2007) Frataktine (CX3CL1) and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res 67: 2331–2338.
20. Martinez C, Hofmann TJ, Marino R, Dominici M, Horwitz EM (2007) Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood 109: 4245–4248.
21. Levy S, Todd SC, Macek HT (1998) CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 16: 89–109.
22. Bauer S, Abdgawad M, Gunnarsson L, Segelmark M, Tapper H, et al. (2007) Prostatease 3 and CD177 are expressed on the plasma membrane of the same subset of neutrophils. J Leukoc Biol 81: 458–464.
23. Kim MY, Oskarsson T, Achariya S, Nguyen DX, Zhang XL, et al. (2009) Tumor self-seeding by circulating cancer cells. Cell 139: 1315–1326.

Acknowledgments
The authors wish to thank all the physicians and pathologists that have collected and centralized the samples in Genoa, and the parents and legal guardians that have allowed the use of their children’s samples for research studies. The excellent technical support of Mrs Barbara Carlini and Fabiana Malaguti, Gaslini Institute, Genoa, is deeply acknowledged. The authors also thank Dr A. Capurro, Genoa, Italy for editing.

Author Contributions
Conceived and designed the experiments: MVC GP. Performed the experiments: FM PS SS PF FG SM SB KM GA. Analyzed the data: CG RH GT MVC VP. Contributed reagents/materials/analysis tools: FG SM SB GA. Wrote the paper: FM PS MVC.
27. Bieche I, Chavey C, Andreiu C, Bussan M, Vacher S, et al. (2007) CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer 14: 1039–1052.

28. Tang Z, Yu M, Miller F, Berk RS, Tromp G, et al. (2008) Increased invasion through basement membrane by CXCL7-transfected breast cells. Am J Surg 196: 690–696.

29. Bassili M, Birman E, Schor NF, Saragovi HU (2010) Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo. Cancer Chemother Pharmacol 65: 1047–1056.

30. Castriconi R, Dondoro A, Augugliaro R, Bovet P, Carnemolla B, et al. (2004) Identification of Hg-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A 101: 12640–12645.

31. Ghavami S, Kerkhoff C, Chazin WJ, Kadkhoda K, Xiao W, et al. (2008) S100A8/9 induces cell death via a novel, RAGE-independent pathway that involves selective release of Smac/DIABLO and Omi/HiBiA2. Biochim Biophys Acta 1763: 297–311.

32. Vogl T, Trnabrock K, Ludwig S, Leukert N, Ehrhardt C, et al. (2007) Mrp10 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 13: 1042–1049.

33. Scaruffi P, Morandi F, Gallo F, Stigliani S, Parodi S, et al. (2011) Bone marrow of neuroblastoma patients shows downregulation of CXCL12 expression and presence of IFN signature. Pediatr Blood Cancer. E-pub ahead of print Oct 17.

34. Cross SS, Hamdy FC, Deloulme JC, Rehman I (2005) Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 46: 256–269.

35. Ito Y, Arai K, Ryushi, Nozawa, Yoshida H, et al. (2005) S100A9 expression is significantly linked to dedifferentiation of thyroid carcinoma. Pathol Res Pract 201: 551–556.

36. Ghavami S, Rashidi I, Dattilo BM, Ershaghi M, Chazin WJ, et al. (2008) S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol 83: 1484–1492.

37. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, et al. (2008) The S100A8/serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 10: 1349–1355.

38. Rouas-Freis N, Moreau P, Menier C, LeMaoult J, Carosella ED (2007) Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol 17: 413–421.

39. Paiku B, Lyden D (2009) The metastatic niche: adapting the foreign soil. Nat Rev Cancer 9: 285–293.

40. Pawelek JM, Chakraborty AK (2008) Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat Rev Cancer 8: 377–386.

41. Aliotta JM, Pereira M, Johnson KW, de Paz N, Doomer MS, et al. (2010) Microvesicle entry into marrow cells mediates tissue-specific changes in mRNA by direct delivery of mRNA and induction of transcription. Exp Hematol 38: 233–245.

42. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466–1477.

43. Conte M, Parodi S, De Bernardi B, Milancic C, Mazzocco K, et al. (2006) Neuroblastoma in adolescents: the Italian experience. Cancer 106: 1409–1417.

44. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, et al. (1999) Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 86: 349–363.

45. Pagnan G, Montaldo PG, Pastoreno F, Raffaghello L, Kirchmeier M, et al. (1999) GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fluvastatin. Int J Cancer 81: 257–264.

46. Swerts K, Ambros PF, Brouzes C, Navarro JM, Gross N, et al. (2005) Standardization of the immunocytochemical detection of neuroblastoma cells in bone marrow. J Histochem Cytochem 53: 1433–1440.

47. Ambros IM, Benzait J, Boavida M, Bown N, Caron H, et al. (2003) Quality assessment of genetic markers used for therapy stratification. J Clin Oncol 21: 2077–2084.

48. Viprey VF, Corrias MV, Kagedal B, Oltra S, Swerts K, et al. (2007) Standardization of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET. Eur J Cancer 43: 341–350.